ClinicalTrials.gg
RecruitingNCT05705804Updated Nov 2, 2026

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

An interventional study of Pitavastatin and Pitavastatin plus Ezetemibe in Dyslipidemias and Atherosclerotic Cardiovascular Disease, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.

Planned enrollment
12th of 21
250 · median 252
Started
2023
the only one that year
No phase
2 of 21
1 open now
Registered
20th of 21
by date
Lead sponsor
1 of 21
Yonsei University

Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 2 with no phase, and was the 20th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pitavastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with atherosclerotic cardiovascular disease with metabolic syndrome.

03

Conditions studied

  • Dyslipidemias
  • Atherosclerotic Cardiovascular Disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with dyslipidemia
  2. Patient with diagnosis of clinical atherosclerotic cardiovascular disease (acute coronary syndrome, history of myocardial infarction, stable or unstable angina, history of coronary artery reperfusion, stroke or transient stroke, history of peripheral arterial disease or peripheral arterial reperfusion)
  3. Patients with metabolic syndrome but without diabetes

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of clinical atherosclerotic cardiovascular disease within 1 year
  2. Acute liver disease or persistent unexplained serum or ALT three times the
  3. Allergy or to statins or ezetimibe
  4. Solid organ transplant recipients
  5. History of side effects requiring discontinuation of statin administration
  6. Pregnant women, potentially pregnant or lactating women
  7. less than 3 years
  8. If it is judged that follow-up for more than 1 year is not possible
  9. If the patient is unable to understand or read the consent form
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Group P

    Pitavastatin 4mg group

    Drug: Pitavastatin

  • Experimental
    Group PE

    Pitavastatin 4 mg Ezetimibe 10 mg combined administration group

    Drug: Pitavastatin plus Ezetemibe

  • Active comparator
    Group A

    Atorvastatin 40 mg administration group

    Drug: Atorvastatin

Interventions

  • Pitavastatin 4 mg will be given.

  • DrugPitavastatin plus Ezetemibe

    Pitvastatin 4 mg plus ezetemibe 10 mg will be given.

  • Atorvastatin 40 mg will be given.

06

What researchers measure

Primary outcomes

  1. Change form baseline homeostatic model assessment for insulin resistance (HOMA-IR) at 24 weeks

    Changes of homeostatic model assessment for insulin resistance (HOMA-IR) form baseline to 24 weeks will be compared among the three groups.

    Time frame: At 24 weeks

Secondary outcomes

  1. Proportion of fasting glucose ≥100 mg/dL

    Time frame: At 24 weeks

  2. Proportion of HbA1C ≥6.5%

    Time frame: At 24 weeks

  3. Proportion of new-onset diabetes mellitus

    Time frame: At 24 weeks

  4. Changes of HOMA-β at 24 weeks

    Time frame: At 24 weeks

  5. Changes of fasting glucose at 24 weeks

    Time frame: At 24 weeks

  6. Changes of insulin at 24 weeks

    Time frame: At 24 weeks

  7. Changes of HbA1c at 24 weeks

    Time frame: At 24 weeks

  8. Changes of triglyceride at 24 weeks

    Time frame: At 24 weeks

  9. LDL-cholesterol change at 24 weeks

    Time frame: At 24 weeks

  10. HDL-cholesterol change at 24 weeks

    Time frame: At 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Feb 2028, 56 months after the start.

Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 56 months is above that.

Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2027 → Feb 2028 and completion Jun 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Jan 31, 2023
StartActual
Jun 13, 2023
Primary completionEst.
Feb 29, 2028was May 2027
CompletionEst.
Aug 5, 2028was Jun 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 1, 2027→Feb 29, 2028
Nov 2, 2026
Study completion
Jun 1, 2027→Aug 5, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion May 1, 2027→Feb 29, 2028
    Study completion Jun 1, 2027→Aug 5, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05705804
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Jun 13, 2023
Primary completion
Feb 29, 2028 (estimated)
Completion
Aug 5, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Byeong-Keuk Kim
Contact
KIMBK@yuhs.ac
82-2-2228-8465
Byeong-Keuk Kim
principal investigator · Severance Cardiovascular Hospital, YONSEI UNIVERSITY COLLEGE OF MEDICINE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion